Apellis Pharmaceuticals
APLS · NASDAQ
Price unavailable right now.
No price history for this range.
Key indicators
APLS profitability and balance sheet ratios
EPS $0.142 in Mar 2026, against -$0.7351 a year earlier.
| Period | EPS |
|---|---|
| Jun 2024 | -$0.3039 |
| Sep 2024 | -$0.4624 |
| Dec 2024 | -$0.2919 |
| Mar 2025 | -$0.7351 |
| Jun 2025 | -$0.3345 |
| Sep 2025 | $1.66 |
| Dec 2025 | -$0.4654 |
| Mar 2026 | $0.142 |
Income statement
No financial statements are reported for Apellis Pharmaceuticals.
Balance sheet
What the company owns and owes at period end
Total assets
Total liabilities
| Line item | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|
| Total assets | $1.1B | $1.1B | $1.1B |
| Total liabilities | $0.7B | $0.7B | $0.7B |
| Shareholder equity | $0.4B | $0.4B | $0.4B |
| Cash and short-term investments | $0.5B | $0.5B | $0.4B |
| Total debt | $0.5B | $0.5B | $0.5B |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.